Island Pharmaceuticals Advances Galidesivir Dose Study with USAMRIID Collaboration

Strategic Expansion of USAMRIID Partnership

Island Pharmaceuticals (ASX:ILA) has taken a significant step forward in its antiviral development program by expanding its Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation. This expansion formalises plans for a Galidesivir dose optimisation study designed to identify the minimally effective dose against the Angola strain of Marburg virus, a highly lethal pathogen.

The agreement cements operational readiness, resolving final study design and resourcing, enabling the trial to proceed on schedule within USAMRIID’s Biosafety Level 4 (BSL-4) facilities, the only Department of War laboratory equipped for maximum containment of such hazardous viruses.

Dose Optimisation Study Details and Objectives

The upcoming study will evaluate varying dose regimens and treatment initiation times, with dosing commencing either 24 or 48 hours post-exposure, continuing twice daily via intravenous administration over 14 days. The primary endpoint is survival at 28 days, supplemented by clinical signs, viral load assessments, pharmacokinetics, and detailed pathology analyses.

Island aims to generate critical translational data supporting progression to a pivotal confirmatory efficacy study, a prerequisite for potential FDA approval under the Animal Rule pathway. This two-stage development approach follows encouraging non-human primate (NHP) data showing approximately 94% survival in Galidesivir-treated subjects infected with the Marburg Musoke strain, compared to zero survival in placebo controls.

Positioning Within Global Biodefence Landscape

CEO Dr David Foster highlighted the strategic importance of partnering with USAMRIID, describing it as a premier biodefence research organisation. Securing access to BSL-4 infrastructure for this study represents a major operational achievement and materially de-risks a critical component of Island’s development pathway.

The company is advancing its global biodefence positioning amid rising concerns over filoviruses such as Marburg and Ebola. Galidesivir’s broad-spectrum antiviral activity against multiple high-consequence RNA viruses places it among a select group of candidates with demonstrated survival benefits and potential for government procurement.

Island is concurrently negotiating with other BSL-4 facilities and engaging with US government stakeholders to explore regulatory, scientific, and biodefence collaborations, including stockpiling opportunities.

Next Steps and Timeline

Operational planning is underway, with the dose optimisation study expected to commence next quarter and topline data anticipated in the second half of 2026. The dosing phase itself is projected to run about 30 days, though extensive preparation is required for high-containment studies.

Following successful dose optimisation, Island plans to leverage the efficacy and pharmacokinetic data to design a pivotal confirmatory trial essential for potential FDA approval. This aligns with the company’s broader Animal Rule development program, which has been progressing steadily with recent GMP manufacturing underway and enhanced US biodefence expertise appointments.